RxDoctor Payments Data

Kimberly Cingle, MD

Ophthalmology · Kent, OHNPI 1275567885

Payments from drug & device makers

$770in general payments, 2019–2025

Across 31 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$226
  • Amgen$125
  • AbbVie$89
  • Alcon$87
  • Shire North American Group Inc$59
  • Astellas Pharma US Inc$35
  • plus $150 from 7 others

What the payments were for

  • Food & beverage$770100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$770 in reported general payments places this provider in the 40th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$138,801
Medicare patients
534
Services billed
1,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine56$58,574
LumiganBimatoprost102$43,965
Travoprost122$23,249
XiidraLifitegrast13$13,907
Brimonidine Tartrate187$13,082
Prednisolone Acetate354$9,845
MoxifloxacinMoxifloxacin Hcl312$8,093
SimbrinzaBrinzolamide/Brimonidine Tart19$6,111
Latanoprost491$5,458
Ketorolac Tromethamine336$5,333
ErythromycinErythromycin Base230$2,195
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,187
Dorzolamide Hcl52$1,283
Bimatoprost14$1,282
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat64$957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$89$102,539158 claims
AlconSimbrinza$87$6,11119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Kent

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →